Table 3 Transition matrix for the treatment pathway metformin+sulfonylureas
| Â | Â | To t+1 | Â | Â | Â |
|---|---|---|---|---|---|
|  |  | Metformin monotherapy | Metformin +SU | Metformin +SU + Basal insulin | Death |
From t | Metformin monotherapy | # | 0.046 | 0 | 60–70 years; 0.021 71–80 years; 0.051 81–85 years; 0.107 |
|  | Metformin +SU | 0 | # | 0.053 | 60–70 years; 0.021 × 1.85 (HR) 71–80 years; 0.051 × 1.85 (HR) 81–85 years; 0.107 × 1.85 (HR) |
|  | Metformin +SU + Basal insulin | 0 | 0 | # | 60–70 years; 0.021 71–80 years; 0.051 81–85 years; 0.107 |
| Â | Death | 0 | 0 | 0 | 1 |